Conference Proceedings
FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma
Amir Iravani, Anna Galligan, Arian Lasocki, Roslyn Wallace, Alison Weppler, George Au Yeung, Tim Akhurst, Nirupa Sachithanandan, Cherie Chiang, Shahneen Sandhu, Rodney Hicks
Journal of Nuclear Medicine | Society of Nuclear Medicine and Molecular Imaging | Published : 2020
Abstract
Objectives: Hypophysitis and thyroiditis are among the most commonly reported immune-related adverse events (irAEs) following combined ipilimumab/nivolumab therapy for melanoma. The role of 18F-FDG PET/CT (FDG-PET) in the evaluation of these endocrinopathies has not been systematically assessed. Methods: Between 2016 to 2019, all patients (pts) with advanced melanoma who received combined ipilimumab/nivolumab therapy were reviewed. Pts with a pre-treatment and post-treatment FDG-PET were included. On FDG-PET, PET-hypophysitis was defined as a discernable new uptake in the pituitary fossa and PET-thyroiditis as new diffuse uptake in the thyroid. Pre- and post-treatment SUVmax of pituitary a..
View full abstract